Formulations Platform Overview
Our portfolio spans a diverse array of adjuvant classes, optimized for:
• Enhanced antigen presentation and immunological memory
• Induction of robust Th1-biased responses
• Compatibility with protein subunit, inactivated, and vector-based vaccines
• Stability under thermal stress for deployment in low-resource settings
Our adjuvant portfolio
TLR4 Ligands
GLA and SLA are synthetic hexa-acylated monophosphoryl lipid A molecules with established safety and activity profile from Phase 1/2 clinical testing.
GLA and SLA were designed as synthetic analogues to the hexa-acylated component of the naturally derived MPL®
GLA and SLA are highly pure defined compounds designed for optimal TLR4 receptor binding, enabling substantially lower clinical dose compared to MPL®. In a squalene emulsion, they can also be lyophilized for single vial thermostable presentation or can be spray dried for thermostable nasal dry powder delivery.
Scientific Publications
GLA-SE Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
SLA-SE Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
GLA-SE enhances malaria antigen-specific antibodies and circulating Tfh in humans
(Hill, 2019. J Exp Med.)
Read More
TLR7/8 Ligands
3M-052 (TLR7/8) is synthetic lipidated imidazoquinoline.
AAHI develops adjuvants formulations with 3M-052 proven to elicit strong Th1-biased immune responses with exceptional durability.
Scientific Publications
3M-052-SE Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
3M-052-Alum Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
3M-052-AF Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
Read More
Dual Agonist
Co-formulated TLR4 + TLR7/8 liposomal adjuvant systems for synergistic activation of innate and adaptive immune responses.
AAHI’s dual agonist develops a strong mucosal immune response as well as a Th1-type systemic response.
TLR Ligands + Alum
TLR Ligands + Alum combines lipid-based TLR 4 or TLR 7/8 agonists absorbed to alum that has been clinically tested in humans and promotes a TH1-skewed immune responses.
Scientific Publications
3M-052-Alum Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
AAHI takes a formulation approach to enhance adjuvant activity, including antibody and Th1-type cellular immune responses.
(Fox, 2016. J Control Release.)
Read More
Saponin QS-21
QS-21 is a saponin derived from Quillaja Saponaria associated with inflammasome activation.
cGMP QS-21 is obtained by AAHI from bark extract at high yield and high purity using a novel purification process.
AAHI’s QS-21 has been formulated in liposomes with GLA and tested in Phase 1 clinical trials.
Scientific Publications
GLA-LSQ Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
SLA-LSQ Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
An adjuvanted pregnancy-associated malaria vaccine candidate proved safe and immunogenic in a phase 1 clinical trial.
(Nielsen, 2019. Clin Infect Dis.)
Read More
NanoAlum
A nanoparticulate alum formulation designed for improved delivery and immune activation; enhances Th1-type adjuvant activity compared to alum.
Aqueous Nanosuspension
Stable dispersion of adjuvant nanoparticles enabling enhanced uptake and immune priming.
Particularly suitable for intradermal delivery.
AAHI’s aqueous Nanosuspension have advanced into human clinical trials.
Scientific Publications
GLA-AF Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
SLA-AF Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
3M-052-AF Adjuvant Portfolio
Vaccine Adjuvant Compendium, NIH
Read More
Why Choose AAHI Adjuvants
Developing affordable & effective health solutions
We are focused on creating technologies that improve the body’s natural response to disease.
Get in touch
Potent & Durable Immunity
Designed to boost both arms of the immune system—T cells and neutralizing antibodies—for sustained protection, especially in populations with waning or immature immunity.
Cross-Variant Protection
Optimized to induce broad responses capable of neutralizing emerging viral variants and supporting multivalent vaccine design.
Low-Resource Compatibility
Engineered for thermal stability using spray- and freeze-drying technologies. Stable at ambient temperatures up to 3 months—reducing cold chain dependency.
What We Do
Collaborate With Us
We welcome collaboration with academic, biotech, and pharmaceutical partners seeking to accelerate vaccine development.
- Access proprietary adjuvant formulations
- Initiate preclinical evaluation partnerships
- Co-develop custom formulations for specific indications
